Login / Signup

The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review.

Ruth A ReitzelJoel RosenblattBahgat Z GergesAndrew JarjourAna Fernández-CruzIssam I Raad
Published in: JAC-antimicrobial resistance (2020)
Emergence of new resistance to combinations of M/R, minocycline/rifampicin/chlorhexidine (M/R/CH) and chlorhexidine/silver sulfadiazine (CHXSS) was rare. No clinical trials confirmed its occurrence and some refuted it. The risk of development of new resistance to these antimicrobial combinations appears more fear-based than substantiated by clinical and experimental evidence but warrants continued surveillance.
Keyphrases
  • antimicrobial resistance
  • clinical trial
  • mycobacterium tuberculosis
  • surgical site infection
  • pulmonary tuberculosis
  • risk assessment
  • staphylococcus aureus
  • gold nanoparticles
  • room temperature